C4 Therapeutics to Participate in Upcoming March Investor Conferences

Rhea-AI Summary

C4 Therapeutics (Nasdaq: CCCC), a clinical-stage biopharmaceutical company focused on targeted protein degradation science, has announced its participation in two major investor conferences in March 2025.

The company will present at the TD Cowen 45th Annual Healthcare Conference on March 3rd at 9:10 am ET in Boston, MA. A live webcast will be accessible through the company's website's Events & Presentations page, with replay available for approximately 30 days after the event.

Additionally, management will attend the Leerink Partners Global Healthcare Conference on March 9th in Miami, FL.

News Market Reaction

-3.99%

1 alert

-3.99% News Effect

On the day this news was published, CCCC declined 3.99%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in two upcoming March investor conferences.

• TD Cowen 45^th Annual Healthcare Conference:
  • Management will present on March 3^rd at 9:10 am ET in Boston, MA. The live webcast will be available on the Events & Presentations page of the company’s website. The archived replay of the webcast will be available for approximately 30 days following the live event.

• Leerink Partners Global Healthcare Conference:
  • Management will participate in the conference on March 9^th in Miami, FL.

About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO^® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.

Contacts:
Investors:
Courtney Solberg
Senior Manager, Investor Relations
CSolberg@c4therapeutics.com

Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com

FAQ

When is C4 Therapeutics (CCCC) presenting at the TD Cowen Healthcare Conference in March 2025?

C4 Therapeutics will present at the TD Cowen 45th Annual Healthcare Conference on March 3rd, 2025, at 9:10 am ET in Boston, MA.

How long will the CCCC TD Cowen conference webcast be available for replay?

The webcast replay will be available for approximately 30 days following the live event on the company's website.

Which investor conferences is C4 Therapeutics (CCCC) attending in March 2025?

C4 Therapeutics is participating in two conferences: the TD Cowen 45th Annual Healthcare Conference in Boston on March 3rd and the Leerink Partners Global Healthcare Conference in Miami on March 9th.

Where can investors access the CCCC TD Cowen conference presentation webcast?

Investors can access the live webcast through the Events & Presentations page of C4 Therapeutics' company website.